{"id":"W4395109428","doi":"10.1093/rheumatology/keae163.295","title":"E068 Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2","year":2024,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University Health Network","funders":"Cilag; Samsung; LEO Pharma; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Biogen; Gilead Sciences; Eisai; Chugai Pharmaceutical; Celltrion; Sanofi; Amgen; Pfizer; Galderma; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Axial spondyloarthritis; Physical therapy; Internal medicine; Disease; Sacroiliitis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004334828,0.0008088718,0.001857547,0.0003989337,0.0005509828,0.001387507,0.0007888351,0.001588208,0.005481504],"category_scores_gemma":[0.003350753,0.0004560539,0.002526823,0.0005449984,0.000558719,0.0008534453,0.0005461145,0.002545977,0.001020788],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005993284,"about_ca_system_score_gemma":0.001505528,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009297109,"about_ca_topic_score_gemma":0.002903554,"domain_scores_codex":[0.9982204,0.0009744136,0.0001868307,0.0001866241,0.0002377836,0.0001940243],"domain_scores_gemma":[0.9975408,0.0006390567,0.0007534102,0.0001769771,0.0004547267,0.000434912],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7778538,0.03131719,0.03343029,0.004623466,0.006380971,0.0002661178,0.0003879429,0.001142725,0.01993337,0.0004326813,0.0141193,0.1101121],"study_design_scores_gemma":[0.5324728,0.3485012,0.08727098,0.0007986424,0.005537518,0.0008417199,0.0003223238,0.001107547,0.004900409,0.0004822679,0.0176383,0.0001264388],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9560499,0.01960653,0.0009644909,0.001787077,0.0004230871,0.005521239,0.009009213,0.0001093333,0.006529122],"genre_scores_gemma":[0.9690031,0.006182984,0.002652417,0.002420445,0.0003532548,0.00635698,0.01047757,0.00004772,0.002505363],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005481504,"threshold_uncertainty_score":0.02292502,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01646879637201244,"score_gpt":0.2935829170475122,"score_spread":0.2771141206754998,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}